Corrects the Company’s Misrepresentations of Vivo’s Capital Contributions, Which Have Been Critical to Sinovac’s Commercial Success and Ability to Return Capital to Shareholders Calls on All ...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on ...

BEIJING, January 22, 2026--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq ...

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, ...

It is time to act. Your vote at the upcoming Special Meeting of Shareholders will shape SINOVAC’s future. SAIF has called this Special Meeting to reconstitute a remnant of the Former Board that the UK ...

We are writing to set the record straight in response to the Vivo group’s recent press releases, lawsuits and other actions against SINOVAC and the Board, particularly those related to the Board’s ...

Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension Company’s revenue may have risen 80-fold or ...